Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Camurati-Engelmann Syndrome 1

Interventions

pembrolizumab 185Carboplatin 133Paclitaxel 102Cisplatin 102Gemcitabine 86Pemetrexed 80durvalumab 75Nivolumab 66Docetaxel 56atezolizumab 52Bevacizumab 50Cyclophosphamide 49Dexamethasone 45Capecitabine 45Oxaliplatin 43130-nm albumin-bound paclitaxel 42Rituximab 40Fulvestrant 39Lenalidomide 38Fluorouracil 38Prednisone 32osimertinib 31olaparib 29Leucovorin 29venetoclax 28fludarabine 28Trastuzumab 27Doxorubicin 27Etoposide 25Cetuximab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × INDUSTRY × LY3300054 × Clear all
NCT02937272 2026-04-03

A Study of LY3200882 in Participants With Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
223 enrolled

Camurati-Engelmann Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡